Bimatoprost grenod(Bimatoprost grenod) - 药物靶点：Prostanoid receptor_在研适应症：高眼压症，开角型青光眼_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Bimatoprost-NO、NO-bimatoprost、K 911

+ [5]

靶点

Prostanoid receptor

作用方式

激动剂、供体

作用机制

前列腺素类受体家族激动剂、一氧化氮供体

治疗领域

眼部疾病

在研适应症

高眼压症开角型青光眼

非在研适应症-

原研机构

Nicox SA

在研机构

Kowa Co., Ltd.

欧康维视生物医药（上海）有限公司Siegfried Irvine

+ [2]

非在研机构-

权益机构

欧康维视生物医药（上海）有限公司

Kowa Co., Ltd.

Nicox SA

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C31H46N2O8

InChIKeyNTQMJNDRYSYWNJ-BPXWCPHMSA-N

CAS号1194396-71-8

关联

5

项与 Bimatoprost grenod 相关的临床试验

NCT05938699

/ Completed临床2/3期

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution - A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial (Whistler)

This is a double-masked, placebo-controlled study which will determine the action of NCX 470 ophthalmic solution, 0.1% on aqueous humor dynamic parameters in healthy volunteers or subjects with OHT.

开始日期2023-12-12

申办/合作机构

Nicox Ophthalmics, Inc.

CTR20223164

/ Completed临床1期

0.1%NCX 470 滴眼液在中国健康志愿者中的全身药代动力学、安全性和耐受性研究

主要目的：评价0.1% NCX 470滴眼液单次和多次给药在中国健康受试者中的药代动力学特征次要目的：评价0.1% NCX 470滴眼液单次和多次给药在中国健康受试者中的安全性和耐受性

开始日期2023-02-22

申办/合作机构

Nicox Ophthalmics, Inc.

[+2]

NCT04630808

/ Completed临床3期

A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

开始日期2020-11-09

申办/合作机构

Nicox Ophthalmics, Inc.

100 项与 Bimatoprost grenod 相关的临床结果

登录后查看更多信息

100 项与 Bimatoprost grenod 相关的转化医学

登录后查看更多信息

100 项与 Bimatoprost grenod 相关的专利（医药）

登录后查看更多信息

9

项与 Bimatoprost grenod 相关的文献（医药）

2024-12-01·Contemporary Clinical Trials

A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study

Article

作者: Mansberger, Steven L ; Hubatsch, Doug ; Fechtner, Robert ; Lopez, Krisi

PURPOSE:

To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design.

PATIENTS AND METHODS:

In this prospective, multicenter trial, subjects were randomized 1:1:1 to NCX 470 0.065 %, NCX 470 0.1 %, or latanoprost 0.005 % dosed topically to both eyes once daily. After at least 30 subjects were assigned to each group, interim analysis was undertaken at 2 weeks and an independent committee selected the final NCX 470 dose for the full 12-week trial.

RESULTS:

The interim analysis included 103 subjects. The least-squares mean (95 % confidence interval [CI]) difference in diurnal intraocular pressure (IOP) was -1.51 mmHg (-2.88, -0.14) in the NCX 470 0.065 % group (p = 0.0308) and - 1.71 mmHg (-3.04, -0.38) in the NCX 470 0.1 % group (p = 0.0123), both favoring NCX 470 over latanoprost. The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). NCX 470 0.1 % was selected as the final dose and the NCX 470 0.065 % dose arm was terminated with subsequent subjects randomized 1:1 to NCX 470 0.1 % or latanoprost.

CONCLUSION:

Both concentrations of the NO-donating bimatoprost NCX 470 lower IOP more than latanoprost following 2 weeks of daily therapy. This adaptive dose selection design allowed identification of the optimal dose of NCX 470 with reduced trial costs, recruitment time, and the number of patients exposed to study medication.

2024-08-01·Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs

Article

作者: Unser, Andrea ; Torrejon, Karen Y. ; Ahmed, Feryan ; Hubatsch, Douglas A ; Impagnatiello, Francesco ; Torrejon, Karen Y ; Bastia, Elena ; Hubatsch, Douglas A. ; Galli, Corinna ; Toris, Carol ; Fan, Shan

Purpose: To determine NCX 470 (0.1%) and Lumigan^® (bimatoprost ophthalmic solution, 0.01%-LUM) intraocular pressure (IOP)-lowering activity after single or repeated (5 days) dosing along with changes in aqueous humor (AH) dynamics. Methods: Ocular hypotensive activity of NCX 470 and LUM was compared with vehicle (VEH) in Beagle dogs using TonoVet^®. Non-human primates (NHP) and bioengineered three-dimensional (3D) human Trabecular Meshwork/Schlemm's Canal (HTM/HSC™) constructs exposed to transforming growth factor-β2 (TGFβ2) were used to monitor NCX 470 and LUM-induced changes in AH dynamics. Results: NCX 470 (30 μL/eye) showed greater IOP reduction compared with LUM (30 μL/eye) following single AM dosing [maximum change from baseline (CFB_max) = -1.39 ± 0.52, -6.33 ± 0.73, and -3.89 ± 0.66 mmHg (mean ± standard error of the mean) for VEH, NCX 470, and LUM, respectively]. Likewise, repeated 5 days daily dosing of NCX 470 resulted in lower IOP than LUM across the duration of the study (average IOP decrease across tests was -0.45 ± 0.22, -6.06 ± 0.15, and -3.60 ± 0.22 mmHg for VEH, NCX 470, and LUM, respectively). NCX 470 increased outflow facility (Cfl) in vivo in NHP (Cfl_VEH = 0.37 ± 0.09 μL/min/mmHg and Cfl_NCX470 = 0.64 ± 0.17 μL/min/mmHg) as well as in vitro (C_HTM/HSC) in HTM/HSC constructs (C_HTM/HSC__VEH = 0.47 ± 0.02 μL/min/mm²/mmHg and C_HTM/HSC__NCX470 = 0.76 ± 0.03 μL/min/mm²/mmHg). In addition, NCX 470 increased uveoscleral outflow (Fu_VEH = 0.62 ± 0.26 μL/min and Fu_NCX470 = 1.53 ± 0.39 μL/min with episcleral venous pressure of 15 mmHg) leaving unaltered aqueous flow (AHF_VEH = 2.03 ± 0.22 μL/min and AHF_NCX470 = 1.93 ± 0.31 μL/min) in NHP. Conclusions: NCX 470 elicits greater IOP reduction than LUM following single or repeated dosing. Data in NHP and 3D-HTM/HSC constructs suggest that changes in Cfl and Fu account for the robust IOP-lowering effect of NCX 470.

2024-08-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study

Article

作者: Mansberger, Steven ; Ziebell, Sara ; Lopez, Krisi ; Hubatsch, Doug ; Fechtner, Robert ; Mulaney, Jay ; Branch, James

PURPOSE:

To compare intraocular pressure (IOP)-lowering efficacy and safety of NCX 470, a nitric oxide (NO)-donating bimatoprost, to latanoprost in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

DESIGN:

Prospective, phase 3, randomized, adaptive dose-selection, double-masked, parallel-group trial.

METHODS:

691 subjects with OAG or OHT and unmedicated IOP ≥26 mmHg at 8AM, ≥24 mmHg at 10AM, and ≥22 mmHg at 4PM in the study eye were randomized to NCX 470 0.065%, NCX 470 0.1%, or latanoprost 0.005%. An interim analysis was performed to select the final dose of NCX 470. We evaluated noninferiority of NCX 470 versus latanoprost, based on IOP reduction from baseline at 8AM and 4PM at 2 weeks, 6 weeks, and 3 months.

RESULTS:

661 subjects were analyzed; IOP was significantly reduced at all on-treatment time points, with reductions ranging from 8.0 to 9.7 mmHg (P < .0001 at each time point) in the NCX 470 0.1% group. Mean IOP reductions were greater with NCX 470 0.1% than latanoprost 0.005% at all 6 time points and significantly greater (P < .05) at 4 of the 6 time points. The most common adverse event was conjunctival/ocular hyperemia.

CONCLUSION:

The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.

107

项与 Bimatoprost grenod 相关的新闻（医药）

2025-08-26

·GlobeNewswire-Health Care

Nicox Announces Shareholder Q&A Webpage Available

Press Release Nicox Announces Shareholder Q&A Webpage AvailableAugust 26, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, www.nicox.com, including information on the most frequently asked questions for shareholders in the form of a Q&A about Nicox and its business. The Q&A page can be reached here: Q&A Any investor questions can be addressed to communications@nicox.com.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese, and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_Q&AAugust2025_PR_FINAL

2025-08-23

·药明康德

BMI显著下降！突破性疗法获FDA优先审评资格；创新眼药水达3期试验主要终点！上市申请即将递交……

BMI显著下降！突破性疗法获FDA优先审评资格 Rhythm Pharmaceuticals宣布，美国FDA已受理其药品setmelanotide的补充新药申请（sNDA），用于治疗继发性下丘脑性肥胖，并授予优先审评资格。该申请的PDUFA目标日期为2025年12月20日。与此同时，欧洲药品管理局（EMA）也已受理该药品扩展适应症的监管申请。Setmelanotide是一种黑皮质素-4受体（MC4R）激动剂，此前已获FDA与EMA批准，用于治疗由Bardet-Biedl综合征及POMC、PCSK1或LEPR基因缺陷导致的肥胖。该疗法曾获FDA授予突破性疗法认定，用于治疗下丘脑性肥胖。本次扩展适应症申请主要基于关键临床3期试验TRANSCEND的积极结果。这是一项全球性研究，纳入120例继发性下丘脑性肥胖患者。试验达到主要终点：setmelanotide治疗组患者在52周时平均身体质量指数（BMI）较基线下降16.5%，而安慰剂组则上升3.3%，两组间差异具有高度统计学意义（p<0.0001）。经安慰剂校正后，治疗组患者BMI降低幅度达19.8%，显示出显著且具有临床意义的疗效。创新眼药水达3期试验主要终点！上市申请即将递交 Nicox宣布，其创新一氧化氮（NO）释放型比马前列素滴眼液NCX 470 0.1%在Denali临床3期试验中达到了主要终点。在这项涵盖696例开角型青光眼或眼压过高患者的研究中，每日一次NCX 470给药在降低基线眼压（IOP）方面，与标准治疗相比，达到非劣效性。结果显示，NCX 470的眼压下降幅度为7.9至10.0 mmHg，而标准治疗为7.1至9.8 mmHg。在预设的次要疗效分析中，NCX 470在六个时间点中的五个时间点在数值上表现出优势，并在其中三个时间点达到统计学显著差异（p<0.05），尽管未能获得整体统计学上的优效性。该结果与该药物在2022年成功完成的首个3期临床试验Mont Blanc一致，进一步确认了NCX 470在降低眼压方面的疗效，为后续的监管申报奠定了坚实基础。公司表示，这一数据支持其计划于2026年上半年向美国FDA递交的新药申请（NDA）。 3.5亿美元！Kite收购体内细胞疗法公司日前，Kite宣布达成协议，将以总额高达3.5亿美元收购Interius BioTherapeutics。Interius是一家专注于体内CAR疗法开发的生物技术公司。此次收购将进一步丰富Kite在细胞治疗领域的专业能力，通过引入Interius的体内整合平台，进一步强化Kite在创新疗法领域的布局。与传统CAR-T疗法需经历细胞采集、改造及回输的繁琐流程不同，Interius的平台可直接在患者体内生成CAR-T细胞，且仅需一次静脉输注即可完成治疗，并无需预处理化疗或复杂的细胞操作。这一“现货型”且个体化的治疗方式有望实现更持久的疗效。平台的模块化架构不仅可快速应用于不同疾病领域，还能在生产规模上具备灵活性，为无法接受现有细胞疗法、尤其是病情进展迅速的患者带来新的治疗机会。参考资料： [1] Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients. Retrieved August 22, 2025 from https://www.nicox.com/wp-content/uploads/EN_NCX470DenaliToplineAugust2025_PR_FINAL.pdf [2] Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity. Retrieved August 22, 2025 from https://www.globenewswire.com/news-release/2025/08/20/3136704/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Acceptance-of-sNDA-for-Setmelanotide-in-Acquired-Hypothalamic-Obesity.html [3] Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform. Retrieved August 22, 2025 from https://www.businesswire.com/news/home/20250820272168/en/Kite-to-Acquire-Interius-BioTherapeutics-to-Advance-In-Vivo-Platform 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

优先审批突破性疗法免疫疗法细胞疗法临床3期

2025-08-21

·EndPoints

Nicox eyes FDA submission as ocular hypertension drug passes Phase 3

Nicox’s eye drop candidate has cleared a second Phase 3 trial in conditions related to high blood pressure in the eyes, poising the company for an FDA filing in the first half of 2026. The French biotech’s bimatoprost-based drug, called NCX 470, was just as good as standard of care at reducing intraocular pressure, meeting the primary endpoint of the Denali trial. The standard of care is latanoprost eye drops. The study enrolled 696 patients with open-angle glaucoma or ocular hypertension in the US and China, according to Thursday’s release . NCX 470 previously passed a similarly designed Phase 3 trial called MontBlanc in 2022. Nicox is now preparing for a pre-NDA meeting with the FDA along with its partner Kowa. It also plans to share detailed results from the Denali trial at a future ophthalmology meeting. But NCX 470 didn’t meet the study’s secondary endpoint of time-matched change in intraocular pressure versus latanoprost. The treatment did show “statistical superiority” at three of the six time points measured, but fell short of significance in the overall endpoint. Nicox’s drug was also associated with a higher rate of conjunctival hyperaemia (22.0%) compared with latanoprost (9.2%). This happens when the clear membrane in the white part of the eyeball becomes red due to the dilation of blood vessels. Furthermore, 10.1% of patients receiving NCX 470 discontinued treatment versus 6.6% of latanoprost patients. With Thursday’s data, Nicox is set to receive a €5 million ($5.8 million) milestone from Kowa per a licensing pact inked in July. Under the terms of that deal, Kowa has exclusive rights to develop and commercialize NCX 470 in the US and all other markets except for certain Asian countries. Nixon could get up to €127 million in milestones. Ocumension Therapeutics has the rights to NCX 470 in China, Korea and Southeast Asia.

临床3期引进/卖出

100 项与 Bimatoprost grenod 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高眼压症	临床3期	中国	苏州欧康维视生物科技有限公司	2022-01-30
开角型青光眼	临床3期	美国	Nicox Ophthalmics, Inc.	2020-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04630808 (Denali, NEWS) 人工标引	临床3期	开角型青光眼 \| 高眼压症	696	NCX 470 0.1%	鹹鑰餘艱簾獵餘憲製顧(選艱簾糧憲齋壓壓膚鏇) = Mean IOP reductions from baseline ranged from 7.9 to 10.0 mmHg with NCX 470 0.1% compared to 7.1 to 9.8 mmHg with latanoprost, measured at 8 AM and 4 PM across week 2, week 6, and month 3 visits. In a prespecified secondary analysis, NCX 470 achieved statistically significant superiority (p<0.05) at 3 of 6 timepoints, and numerically greater reductions at 5 of 6 timepoints, with differences up to 0.8 mmHg in favor of NCX 470. 廠壓遞鏇蓋夢鹽蓋艱鹽 (廠構鑰繭獵齋觸窪衊積 ) 更多	非劣	2025-08-21
				Latanoprost 0.005%
NCT04445519 (MONT BLANC, CTgov)	临床3期	开角型青光眼	691	NCX 470 0.1% (initial phase of trial) (NCX 470 0.1%)	鏇簾範網獵齋選鑰壓鹹(蓋繭糧窪選廠遞鹽夢獵) = 構鬱衊廠夢壓製醖積蓋蓋構鹹選遞壓網選膚鏇 (顧鑰觸蓋繭築積積艱繭, 3.443) 更多	-	2025-05-30
				Latanoprost (Latanoprost 0.005%)	鏇簾範網獵齋選鑰壓鹹(蓋繭糧窪選廠遞鹽夢獵) = 夢艱鑰糧鏇膚艱蓋遞顧蓋構鹹選遞壓網選膚鏇 (顧鑰觸蓋繭築積積艱繭, 3.349) 更多
NCT05938699 (Whistler, GlobeNewswire) 人工标引	临床3期	高眼压症	18	NCX 470	壓鏇鏇選獵廠壓築築觸(齋蓋顧築憲顧夢獵繭淵) = Changes in aqueous humor flow rate trended towards significance vs. placebo (p=0.072). Outflow facility was positive at 1 pm (p=0.081), significant at 3 pm (p=0.001), as was the diurnal outflow (p=0.004). 廠範襯蓋襯築廠簾窪構 (鏇夢艱簾憲簾醖簾構衊 )	积极	2025-05-14
				Placebo
NCT04445519 (MONT BLANC, Literature) 人工标引	临床3期	开角型青光眼 \| 高眼压症	103	NCX 470NCX 470 0.065 %	齋齋獵構醖範遞襯壓壓(範蓋範鬱鏇觸淵艱積窪) = The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). 廠觸廠夢襯窪鑰範積鏇 (齋鹹窪廠齋顧齋製襯窪 )	积极	2024-12-01
				NCX 470NCX 470 0.1 %
NCT03657797 (Dolomites, CTgov)	临床2期	开角型青光眼	656	NCX 470 (NCX 470 0.021%)	製衊鏇襯鬱鬱壓醖淵簾(艱鬱鹽淵觸廠鹹廠築觸) = 憲膚餘網構築糧襯蓋築窪遞製糧鹽繭蓋鹽範憲 (築構鹹糧積選遞襯鹹憲, 2.606) 更多	-	2022-12-08
				NCX 470 (NCX 470 0.042%)	製衊鏇襯鬱鬱壓醖淵簾(艱鬱鹽淵觸廠鹹廠築觸) = 遞鑰襯繭簾構廠網範鹹窪遞製糧鹽繭蓋鹽範憲 (築構鹹糧積選遞襯鹹憲, 2.511) 更多
NCT04445519 (Mont Blanc, Corporate Publications) 人工标引	临床3期	青光眼	691	NCX 470	壓觸鬱鹹廠範製製膚選(廠膚廠顧網糧遞繭膚選) = 蓋繭鑰鹽鏇鑰窪廠鏇獵窪積繭顧鹹醖積餘鬱蓋 (範構淵製鬱膚衊憲鏇製 ) 更多	非劣	2022-10-31
				Latanoprost	壓觸鬱鹹廠範製製膚選(廠膚廠顧網糧遞繭膚選) = 餘獵窪鏇壓憲築蓋網簾窪積繭顧鹹醖積餘鬱蓋 (範構淵製鬱膚衊憲鏇製 ) 更多
NCT03657797 (Dolomites, AAO2020)	临床2期	低眼压	433	NCX 470 0.021%	齋構範顧選鹹簾鑰觸衊(夢觸製築鹽醖構選願鹹) = The most common adverse event was conjunctival hyperemia. There were no treatment-related serious adverse events or treatment-related systemic adverse events 淵襯顧繭膚襯鑰積構鏇 (繭範鏇繭齋膚淵簾構廠 )	积极	2020-11-13
				NCX 470 0.065%
NCT03657797 (Dolomites, GlobeNewswire) 人工标引	临床2期	青光眼	433	NCX-470	觸衊鹹廠鏇夢衊願選簾(遞築顧蓋製鏇壓製鹹窪) = 範夢窪憲壓願膚襯遞構齋築鹹願淵憲鹹選構廠 (襯獵壓壓構網壓獵獵築 ) 更多	积极	2019-10-02
				Latanoprost	觸衊鹹廠鏇夢衊願選簾(遞築顧蓋製鏇壓製鹹窪) = 繭餘淵顧餘壓願鏇鏇艱齋築鹹願淵憲鹹選構廠 (襯獵壓壓構網壓獵獵築 ) 更多